We identified several tumor-related immune features that correlated with treatment outcome in our cohort, such as baseline tumor PD-L1 and IRF1 nuclear expression, which could, if validated, help guiding ultraprecision radiation therapy combination with ICB. The gene discussed is IRF1; the disease is neoplasm.